問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2025-09-23 - 2028-02-13

Phase II

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic hepatitis B virus (HBV) infection

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
8Sites

Recruiting8Sites

2021-02-26 - 2025-12-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-12-14 - 2026-12-31

Phase III

Active
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    錠劑

Participate Sites
13Sites

Recruiting13Sites

2022-02-01 - 2026-03-30

Phase I/II

Active
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  • Condition/Disease

    Urothelial Carcinoma

  • Test Drug

    皮下注射劑 皮下注射劑

Participate Sites
4Sites

Recruiting4Sites

2020-05-01 - 2025-03-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-03-01 - 2023-07-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-03-01 - 2028-12-31

Phase III

Completed
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  • Condition/Disease

    Idiopathic Pulmonary Fibrosis

  • Test Drug

    PRM-151 (Zinpentraxin Alfa)

Participate Sites
7Sites

Recruiting7Sites

2024-10-03 - 2029-10-04

Phase II/III

Not yet recruiting
A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

  • Condition/Disease

    Kidney Disease

  • Test Drug

    injection

Participate Sites
7Sites

Recruiting7Sites

2021-03-31 - 2027-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting15Sites

2018-12-01 - 2026-03-31

Phase I

Completed
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    皮下注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

1 24 25 26 27 28 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB